FindTrial
Sign In

Comparison between high dose and low dose laser therapy (Nd:YAG laser) for facial pigmentation (melasma)

Comparison of Melasma Area and Severity Index (MASI) scores between low fluence and high fluence Q-switched Nd:YAG laser for refractory melasma: A randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/07/014864
Enrollment
40
Registered
2018-07-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- All patients of refractory melasma who have not shown complete clearance after 6 weeks of topical triple combination therapy and topical sunscreens attending the dermatology OPD

Interventions

Intervention1: High fluence Q-switched Nd:YAG laser therapy: Laser therapy will be provided at a fluence of 5-6 Joules per sq cm for 3 sessions at 4 weekly intervals Control Intervention1: Low fluence

Sponsors

Department of Dermatology JIPMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients of refractory melasma who have not shown complete clearance after 6 weeks of topical triple combination therapy and topical sunscreens attending the dermatology OPD.

Exclusion criteria

Exclusion criteria: 1. Other causes of facial melanosis (such as lichen planus pigmentosus, erythema dyschronicum perstans, pigmented contact dermatitis, post-inflammatory hyperpigmentation) 2. Pregnant and lactating mothers 3. Patients currently using oral contraceptives 4. History of endocrinopathies

Design outcomes

Primary

MeasureTime frame
Post-treatment Melasma Area and Severity Index (MASI) scoresTimepoint: 3 months—

Secondary

MeasureTime frame
Side effectsTimepoint: 3 months—

Countries

India

Contacts

Public ContactDr Rashmi Kumari

JIPMER

rashmi.sreerag@gmail.com9489692199

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026